Sign inJoin waitlistJoin the waitlist

Seth Fagbemi

Clinical Assistant Professor, Department of Medicine-University of Wisconsin School of Medicine and Public Health, Madison, WI · Marshfield Clinic

Credentials: · · ·

History

Marshfield Clinic
Present

Hematology and Medical Oncology
University of Chicago Medical Center
1985–1988
John H. Stroger Jr. Hospital of Cook County
1982–1985
UNIV OF IBADAN COLL OF MED, IBADAN, OYO STATE, NIGERIA
1978–1982

Research

Actions of pinacidil at a reduced potassium concentration: a direct cardiac effect possibly involving the ATP-dependent potassium channel
Journal of Cardiovascular Pharmacology · 1993 · 49 citations
Enzymes in normally perfused and ischaemic dog hearts which release a substance with kinin like activity
Cardiovascular Research · 1989 · 33 citations
Antifibrillatory and profibrillatory actions of selected class I antiarrhythmic agents
Journal of Cardiovascular Pharmacology · 1993 · First of 3 authors · 32 citations

Adedayo Onitilo
3 papers
Jessica Engel
2 papers
Walter Stadler
2 papers
Amina Ahmed
1 paper
Anthony Jaslowski
1 paper
Aung Naing
1 paper
CB
Charles Blanke
1 paper
CR
Christopher Ryan
1 paper
CM
Colleen Mccormick
1 paper
David O'Malley
1 paper
Edward Kim
1 paper
ES
Elad Sharon
1 paper

Clinical trials

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Site PI · Recruiting · Phase 3
Canadian Cancer Trials Group
2025–2031
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2029
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2039
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Site PI · Recruiting · Phase 2, Phase 3
National Cancer Institute (NCI)
2024–2027